Quillivant XR and Tazarotene

• Generic Name: methylphenidate
• Dosage Forms: powder, for oral suspension, extended release
• Other Brand Names: QuilliChew ER, Quillivant XR, Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT, Jornay PM, Metadate ER, Methylin, Relexxii, Ritalin, Ritalin LA, Metadate CD, Ritalin SR, Daytrana, Methylin ER

Quillivant XR (methylphenidate) is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control.

Quillivant XR extended-release oral suspension is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD). The extended-release oral suspension formulation releases methylphenidate into your body throughout the day.

Quillivant XR may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.

• Generic Name: tazarotene topical
• Dosage Forms: n.a.
• Other Brand Names: Avage, Fabior, Tazorac

Treatment of stable plaque psoriasis with ≤20% body surface area involvement.

Combination therapy with a mid-or high-potency topical corticosteroid more effective than either agent alone.

0.1% cream or gel more effective in improving psoriasis manifestations; 0.05% cream or gel associated with less local irritation.

Treatment of mild to moderate acne vulgaris.

Efficacy in patients resistant to oral antibiotics or previously treated with other retinoids not established.

Palliative therapy to improve dermatologic changes (e.g., fine wrinkling, mottled hypo- or hyperpigmentation, benign lentigines) associated with photodamage.

Use as an adjunct to a comprehensive skin care plan and sun avoidance program. (See Administration under Dosage and Administration.)

Does not eliminate or prevent wrinkles, repair photodamaged skin, reverse photoaging, or restore youthful or younger dermal histologic pattern. No mitigating effects on severe manifestations of chronic sunlight exposure (e.g., coarse/deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, dermal elastosis) demonstrated.

Safety and efficacy not established for use in nonwhite (e.g., Asian, Hispanic) patients or Fitzpatrick skin types V and VI.